A free, open symposium showcasing data from the largest ever study of genomic predictors of treatment outcome in epilepsy!
Precision medicine is the key recent conceptual development in the clinical management of the epilepsies. Both disease causation genetics and pharmacogenomics will contribute to the aim of administering the right drug at the right dose to each individual with epilepsy. Over the last four years, the multicentre EpiPGX Consortium, funded through the European Union’s FP7 programme, has explored response genomics for antiepileptic drugs.
This free‐to‐attend symposium will highlight recent outcomes plus work in progress from EpiPGX and will feature presentations from all of the key EpiPGX investigators. In addition, several prominent guest lecturers – including Sameer Zuberi, David Henshall, and Saskia Biskup – will set EpiPGX data in the wider context of epilepsy genomics, epigenomics and genetic diagnostics.
Find more information here: www.epipgx.eu
